topotecan has been researched along with Carcinoma, Renal Cell in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ankenbruck, N; Connelly, CM; Deiters, A; Gardner, L; Naro, Y; Thomas, M; Tivon, Y | 1 |
| Funke, S; Gasis, M; Hanenberg, H; Heikaus, S; Liverts, A; Mahotka, C; Nitsche, V; Schirmacher, P; Toth, C; Wiek, C; Zlachevska, V | 1 |
| Bhattacharya, A; Chintala, S; Durrani, FA; Rustum, YM | 1 |
| Bjarnason, GA; Bocci, G; Di Desidero, T; Jedeszko, C; Kerbel, RS; Lee, CR; Man, S; Paez-Ribes, M; Xu, P | 1 |
| Gabbert, HE; Heikaus, S; Mahotka, C; Pejin, I; Ramp, U | 1 |
| Fleck, C; Hilger, R; Jurkutat, S; Karge, E; Merkel, U; Schimske, A; Schubert, J | 1 |
| Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Dal Bianco, M; De Zorzi, L; Pastorelli, D; Salmaso, F; Zovato, S; Zustovich, F | 1 |
| Casliskan, E; Gabbert, HE; Heikaus, S; Mahotka, C; Ramp, U | 1 |
| Ilson, DH; Law, TM; Motzer, RJ | 1 |
| Déjosez, M; Gabbert, HE; Gerharz, CD; Krieg, A; Mahotka, C; Ramp, U; Walczak, H | 1 |
| Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ | 1 |
1 review(s) available for topotecan and Carcinoma, Renal Cell
| Article | Year |
|---|---|
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan | 2006 |
3 trial(s) available for topotecan and Carcinoma, Renal Cell
| Article | Year |
|---|---|
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan | 2006 |
Phase II trial of topotecan in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan | 1994 |
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
8 other study(ies) available for topotecan and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; MicroRNAs; Small Molecule Libraries; Topotecan | 2018 |
The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Topics: Active Transport, Cell Nucleus; Aniline Compounds; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Mitochondria; Molecular Targeted Therapy; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Topotecan; Tumor Suppressor Protein p53 | 2017 |
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Mice, Nude; MicroRNAs; Selenocysteine; Selenomethionine; Topotecan | 2018 |
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Maximum Tolerated Dose; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Survival Analysis; Topotecan; Xenograft Model Antitumor Assays | 2015 |
PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs.
Topics: Apoptosis; Carcinoma, Renal Cell; Carrier Proteins; Caspase 2; Cell Line, Tumor; CRADD Signaling Adaptor Protein; Death Domain Receptor Signaling Adaptor Proteins; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Topotecan; Tumor Cells, Cultured; Up-Regulation | 2010 |
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carcinoma, Renal Cell; Cisplatin; Dexamethasone; Epidermal Growth Factor; Female; Glucocorticoids; Humans; Kidney; Kidney Neoplasms; Methotrexate; Quinazolines; Rats; Rats, Wistar; Thiophenes; Topotecan; Triiodothyronine | 2002 |
Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Oligonucleotide Array Sequence Analysis; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transcriptional Activation | 2007 |
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Enzyme Inhibitors; Genes, p53; Humans; Kidney Neoplasms; Membrane Glycoproteins; Mutation; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Up-Regulation | 2000 |